Anthem Bioscienc
Anthem Bioscienc Q3 FY26 earnings call: Revenue & Margins
Q3 FY26 earnings call: what management said on revenue, margins and capex.
Guidance rank: #62 of 84 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
The short version
Anthem expects steady progress in revenue with a mid-teens growth (around 15%-16%) for FY26, despite a high base last year. Anthem Biosciences expects steady topline and bottom-line growth with potential to sustain a CAGR similar to the last five years over the next few years.
From Anthem Bioscienc's Q3 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Anthem expects steady progress in revenue with a mid-teens growth (around 15%-16%) for FY26, despite a high base last year.
- Improvement anticipated in FY27 and FY28, with optimism about returning to approximately 20% growth CAGR over the next five years.
- Growth drivers include ramp-up of recently commercialized products, existing commercial products expanding market share, new large pharma customers, and increased demand post-destocking.
- Pipeline is robust with 130-140 early-stage molecules and 6 in Phase-2 likely to move to Phase-3 in 18-30 months.
- Positive outlook on biotech sector tailwinds due to government encouragement and trade deals.
- GLP-1 peptides expected to become significant contributors, though not exceeding 20%-30% of turnover.
2 more points from Anthem Bioscienc's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Anthem Bioscienc said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Unit-4 Expansion: Rs. 1,000 crore CAPEX planned over two years for Unit-4 on a 30-acre land parcel; currently in early stage with ongoing civil work. Major CAPEX spend expected in FY27.
- New Capacity for Biosimilars: A separate new facility planned for CHO cell-based mammalian biosimilars beyond current 200-liter capacity.
- 16 KL Peptide Facility: Replacement cost estimated at about Rs. 200 crore including utilities; already commissioned a state-of-the-art 16 KL commercial peptide manufacturing facility.
2 more points from Anthem Bioscienc's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Anthem Bioscienc said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- Anthem Biosciences currently has a robust order book with around 130 to 140 early-stage pipeline molecules.
- Approximately 5 to 6 molecules are in Phase 2, expected to move to Phase 3 within 18 to 30 months, subject to clinical outcomes.
- Six molecules remain in Phase 3, with 4 recently commercialized.
- The company has added multiple large pharma customers this year, including supply of advanced intermediates and development work for approved products.
- There has been an increase in requests for RFQs (Request for Quotations) in recent quarters, indicating growing demand.
2 more points from Anthem Bioscienc's call on order book
Create a free account to keep reading this call
Anthem Bioscienc — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹611 Cr, net profit ₹190 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Anthem Biosciences Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Natural Capsules Ltd (Q3 FY26)
Q3FY26 revenue from operations: ₹37.75 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q3 FY26 investor presentation — and how it ranks
- Wanbury (Q3 FY26)
Q3FY26 Revenue from Operations: ₹162.45 Crore . Key investor presentation takeaways from Wanbury Ltd's Q3 FY26 investor presentation — and how it ranks against
- Gujarat Themis Biosyn Ltd (Q3 FY26)
43.37 crore, up 9.74% YoY from Rs. Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q3 FY26 investor presentation — and how it ranks against
- Balaxi Pharmaceuticals Ltd (Q3 FY26)
Q3 FY26 revenue: ₹72.54 crore, down marginally by 1% YoY from ₹73.29 crore in Q3 FY25 (Page 19). Key investor presentation takeaways from Balaxi Pharma's Q3 FY2
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Anthem Bioscienc and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Anthem Bioscienc Q3 FY26 results?
Anthem expects steady progress in revenue with a mid-teens growth (around 15%-16%) for FY26, despite a high base last year. Anthem Biosciences expects steady topline and bottom-line growth with potential to sustain a CAGR similar to the last five years over the next few years.
What is Anthem Bioscienc share price analysis?
Anthem Bioscienc currently shows a neutral. The stock trades at a P/E of 84.5 with a market cap of ₹50,132 Cr. Investors should review the full earnings analysis for detailed insights.
Is Anthem Bioscienc planning capital expenditure?
Unit-4 Expansion: Rs.
Keep Anthem Bioscienc on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.